Guidance on Vulvovaginal Candidiasis Drugs
Federal Register Notice: FDA is making available a draft guidance for industry entitled Vulvovaginal Candidiasis: Developing Drugs for Treatment. Its purpose is to assist sponsors in the clinical development of drugs for treating uncomplicated vulvovaginal candidiasis. To download this guidance, click here. To view this notice, click here.